• Nicholas M G Friedman, Caitlin A Molina, and Melody J Glenn.
• Stanford University School of Medicine, 291 Campus Drive, Stanford, CA 94305, United States of America. Electronic address: nfriedm@stanford.edu.
• Am J Emerg Med. 2023 Oct 1; 72: 858785-87.

AbstractOverdose fatalities are increasingly attributed to synthetic opioids, including fentanyl, which may be added to samples of illicit substances unknowingly to the user. As recently as April 2023, the Centers for Disease Control and Prevention has also raised awareness of the risks of xylazine, an animal tranquilizer that has been found in adulterated samples of illicit substance. A growing body of evidence supports the use of drug testing services, including fentanyl and xylazine test strips, to reduce the risks associated with substance use and prevent fatal overdoses. Emergency medical services clinicians serve on the frontline of the opioid epidemic and are uniquely positioned to distribute harm reduction materials. In this article, we advocate for emergency medical services to distribute fentanyl and xylazine test strips. We also critically evaluate legal and other barriers to implementation.Copyright © 2023 Elsevier Inc. All rights reserved.

16 keywords...

hide…